Tetraphase's Xerava antibiotic gets EU approval

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) said the European Commission approved Xerava eravacycline to treat complicated intra-abdominal infections (cIAIs) in adults. The company plans to begin a phased EU launch of the IV broad-spectrum fluorocycline antibiotic next half. Tetraphase said it has not yet announced European pricing...